Tag - GANX

Developments

Gain reports positive topline results from Phase 1 trial of therapy for Parkinson’s

Gain Therapeutics (NASDAQ:GANX) has announced positive results from its Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson’s...

August 29, 2024

Markets

BTIG starts Gain Therapeutics at buy; PT 30

BTIG initiated coverage of Gain Therapeutics (NASDAQ:GANX) with a “buy” rating and $30 price target. The stock closed at $13.98 on April 9. Gain is a computational and medicinal chemistry-based biotechnology company...

April 12, 2021

Tag - GANX

Gain reports positive topline results from Phase 1 trial of therapy for Parkinson’s

BTIG starts Gain Therapeutics at buy; PT 30

General

More